BACKGROUND: Alcohol potentiates GABAergic neurotransmission via action at the GABAA receptor. α1 subunit-containing GABAA receptors have been implicated as mediators, in part, of the behavioral and abuse-related effects of alcohol in rodents. METHODS: We systematically investigated the effects of 1 α1-preferring benzodiazepine agonist, zolpidem, and 2 antagonists, β-carboline-3-carboxylate-tert-butyl ester (βCCT) and 3-propoxy-β-carboline hydrochloride (3-PBC), on oral self-administration of alcohol (2% w/v) or sucrose solution and observable behavior in rhesus macaques. We compared these effects to those of the nonselective benzodiazepine agonist triazolam, antagonist flumazenil, and inverse agonist β-carboline carboxylate (βCCE). RESULTS: Alcohol and sucrose solutions maintained reliable baseline drinking behavior across the study. The α1-preferring compounds did not affect intake, number of sipper extensions, or blood alcohol levels (BALs) at any of the doses tested. Zolpidem, βCCT, and 3-PBC increased latency to first sipper extension in animals self-administering alcohol, but not sucrose, solution. Triazolam exerted biphasic effects on alcohol-drinking behavior, increasing intake at low doses but decreasing BAL and increasing latency at higher doses. At doses higher than those effective in alcohol-drinking animals, triazolam increased sucrose intake and latency. Flumazenil nonsystematically increased number of extensions for alcohol but decreased BAL, with no effects on sucrose drinking. βCCE decreased sipper extensions for alcohol and increased latency for first sucrose sipper extension, but full dose-effect relationships could not be determined due to seizures at higher doses. CONCLUSIONS: Alcohol-drinking animals appeared more sensitive to the effects of GABAergic compounds on drinking behavior. However, these results do not support a strong contribution of α1GABAA receptors to the reinforcing effects of alcohol in primates.
BACKGROUND:Alcohol potentiates GABAergic neurotransmission via action at the GABAA receptor. α1 subunit-containing GABAA receptors have been implicated as mediators, in part, of the behavioral and abuse-related effects of alcohol in rodents. METHODS: We systematically investigated the effects of 1 α1-preferring benzodiazepine agonist, zolpidem, and 2 antagonists, β-carboline-3-carboxylate-tert-butyl ester (βCCT) and 3-propoxy-β-carboline hydrochloride (3-PBC), on oral self-administration of alcohol (2% w/v) or sucrose solution and observable behavior in rhesus macaques. We compared these effects to those of the nonselective benzodiazepine agonist triazolam, antagonist flumazenil, and inverse agonist β-carboline carboxylate (βCCE). RESULTS:Alcohol and sucrose solutions maintained reliable baseline drinking behavior across the study. The α1-preferring compounds did not affect intake, number of sipper extensions, or blood alcohol levels (BALs) at any of the doses tested. Zolpidem, βCCT, and 3-PBC increased latency to first sipper extension in animals self-administering alcohol, but not sucrose, solution. Triazolam exerted biphasic effects on alcohol-drinking behavior, increasing intake at low doses but decreasing BAL and increasing latency at higher doses. At doses higher than those effective in alcohol-drinking animals, triazolam increased sucrose intake and latency. Flumazenil nonsystematically increased number of extensions for alcohol but decreased BAL, with no effects on sucrose drinking. βCCE decreased sipper extensions for alcohol and increased latency for first sucrose sipper extension, but full dose-effect relationships could not be determined due to seizures at higher doses. CONCLUSIONS:Alcohol-drinking animals appeared more sensitive to the effects of GABAergic compounds on drinking behavior. However, these results do not support a strong contribution of α1GABAA receptors to the reinforcing effects of alcohol in primates.
Authors: Jiuzhou Song; Daniel L Koller; Tatiana Foroud; Kristie Carr; Jinghua Zhao; John Rice; John I Nurnberger; Henri Begleiter; Bernice Porjesz; Tom L Smith; Marc A Schuckit; Howard J Edenberg Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-02 Impact factor: 3.568
Authors: Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma Journal: Psychopharmacology (Berl) Date: 2002-09-04 Impact factor: 4.530
Authors: Snjezana Lelas; James K Rowlett; Roger D Spealman; James M Cook; Chunrong Ma; Xiaoyan Li; Wenyuan Yin Journal: Psychopharmacology (Berl) Date: 2002-03-13 Impact factor: 4.530
Authors: James K Rowlett; Roger D Spealman; Snjezana Lelas; James M Cook; Wenyuan Yin Journal: Psychopharmacology (Berl) Date: 2002-11-06 Impact factor: 4.530
Authors: Scott C Harvey; Katrina L Foster; Pete F McKay; Michelle R Carroll; Regat Seyoum; James E Woods; Collette Grey; Cecily M Jones; Shannan McCane; Rancia Cummings; Dynesha Mason; Chunrong Ma; James M Cook; Harry L June Journal: J Neurosci Date: 2002-05-01 Impact factor: 6.167
Authors: Danielle M Dick; John Nurnberger; Howard J Edenberg; Alison Goate; Ray Crowe; John Rice; Kathleen K Bucholz; John Kramer; Marc A Schuckit; Tom L Smith; Bernice Porjesz; Henri Begleiter; Victor Hesselbrock; Tatiana Foroud Journal: Alcohol Clin Exp Res Date: 2002-10 Impact factor: 3.455
Authors: August F Holtyn; V V N Phani Babu Tiruveedhula; Michael Rajesh Stephen; James M Cook; Elise M Weerts Journal: Drug Alcohol Depend Date: 2016-11-04 Impact factor: 4.492
Authors: Xiao Zhang; Koji Yasuda; Robert A Gilmore; Susan V Westmoreland; Donna M Platt; Gregory M Miller; Eric J Vallender Journal: Psychopharmacology (Berl) Date: 2019-03-22 Impact factor: 4.530
Authors: Lais F Berro; Daniela Rüedi-Bettschen; Jemma E Cook; Lalit K Golani; Guanguan Li; Rajwana Jahan; Farjana Rashid; James M Cook; James K Rowlett; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2019-04-08 Impact factor: 3.455
Authors: V V N Phani Babu Tiruveedhula; Kashi Reddy Methuku; Jeffrey R Deschamps; James M Cook Journal: Org Biomol Chem Date: 2015-11-21 Impact factor: 3.876
Authors: Zhiqiang Meng; Lais F Berro; Eileen K Sawyer; Daniela Rüedi-Bettschen; Jemma E Cook; Guanguan Li; Donna M Platt; James M Cook; James K Rowlett Journal: J Psychopharmacol Date: 2019-10-31 Impact factor: 4.153
Authors: N R N Brandão; M Libarino-Santos; E A V Marinho; T S Oliveira; A L N Borges; A P Oliveira; D Oliveira-Campos; N Azevedo-Souza; V F L Santos; L F Berro; A J Oliveira-Lima Journal: Braz J Med Biol Res Date: 2020-06-26 Impact factor: 2.590